The latest price target for CalciMedica (NASDAQ:CALC) was reported by HC Wainwright & Co. on November 14, 2024. The analyst firm set a price target for $16.00 expecting CALC to rise to within 12 months (a possible 390.30% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for CalciMedica (NASDAQ:CALC) was provided by HC Wainwright & Co., and CalciMedica reiterated their buy rating.

There is no last upgrade for CalciMedica

There is no last downgrade for CalciMedica.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CalciMedica, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CalciMedica was filed on November 14, 2024 so you should expect the next rating to be made available sometime around November 14, 2025.

While ratings are subjective and will change, the latest CalciMedica (CALC) rating was a reiterated with a price target of $16.00 to $16.00. The current price CalciMedica (CALC) is trading at is $3.26, which is out of the analyst’s predicted range.